April 3, 2026, 11:48 AM EDT. Spruce Biosciences (SPRB) closed at $70.50, up 31.1% in four weeks. Wall Street analysts set a mean price target of $198.25, implying an 181.2% upside. Targets range from $140 to $283, highlighting variation among analysts. A low standard deviation suggests strong agreement on direction. Analysts also expect earnings to surpass prior estimates, reinforcing bullish sentiment. However, researchers warn price targets may be overly optimistic due to potential conflicts of interest for analysts. Price targets alone shouldn't drive investments but can prompt further fundamental analysis. Investors should consider consensus views alongside other market signals before trading SPRB shares.